Status: Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Participants needed: 82
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Blue Earth Therapeutics LtdUpdated: May 14, 2026Locations: 21
Eligibility criteria
Male subjects, 18 years of age or older with histologically confirmed adenocarci... [+10]
Known hypersensitivity to the therapeutic or diagnostic IMP or any of its consti... [+21]